FLUCICLATIDE F-18 is an 18F-radiolabelled synthetic cyclic peptide containing an RGD motif (Arg-Gly-Asp). It may be used as a tracer in positron emission tomography (PET) imaging. The RGD motif of FLUCICLATIDE F-18 selectively binds to the alpha-V/beta-3 integrin, upregulated on tumor cells and endothelial cells of tumor vasculature. Integrins play an important role in tumor angiogenesis and metastasis. Thus, FLUCICLATIDE F-18 is a potential biomarker of therapeutic response to antiangiogenic inhibitors.

Ioflubenzamide I-131 (also known as 131-I-MIP-1145) is a radiolabeled iodobenzamide derivative developed by Molecular Insight Pharmaceuticals, Inc for metastatic melanoma treatment. The benzamide moiety of Ioflubenzamide I-131 binds to melanin, selectively delivering a cytotoxic dose of gamma and beta radiation to melanin-expressing tumor cells. In human melanoma xenografts, Ioflubenzamide I-131 exhibited diffuse tissue distribution and washout from all tissues except melanin-expressing tumors. The administration of Ioflubenzamide I-131 at 25 MBq in single or multiple doses significantly reduced SK-MEL-3 tumor growth, with multiple doses resulting in tumor regression and durable response for over 125 days. Unfortunately Phase I clinical trial was terminated by unknown reason.

Iodofiltic Acid I-123 is a single-photon branching free fatty acid radiopharmaceutical with potential application in single-photon emission computed tomography (SPECT). Assessment of fatty acid metabolism by radionuclide techniques has a potential role for the early detection of myocardial ischaemia and the assessment of the severity of ischaemic heart disease. The Iodofiltic Acid I-123 scan is preferable because it can provide suitable information for risk stratification just after an acute myocardial infarction (AMI) without requiring the patient to exercise; it can also detect previous ischaemic insult even after recovery of myocardial perfusion, the so- called "ischaemic memory".

Diotyrosine I 131 is the diagnostic aid manufactured by Abbott.

Ioxabrolic Acid is triiodobenzoic acid derivative and iodine-containing radiopharmaceutical

3'-[(18)F]fluoro-3'-deoxythymidine [[(18)F]-FLT or ALOVUDINE F-18], a tracer for positron emission tomography (PET) that is used for imaging of proliferation in human malignant lymphoma. This compound is also useful for making a proper diagnosis and monitoring treatment response of aplastic anemia patients, because can show overview of the bone marrow compartment in aplastic anemia.

A radioconjugate of synthetic active thyroid hormone, liothyronine (T3), labeled with Iodine 131. Liothyronine involves many important metabolic functions and is essential to the proper development and differentiation of all cells. I131 liothyronine may be used in radiotherapy in thyroid cancers.

Iodocetylic Acid I-123 is a radiolabeled derivative of cetylic acid. Iodocetylic Acid I-123 was studied as for in vivo diagnosis of the myocardium.

PET imaging using 2-[11C]thymidine (dThd) was developed as a measure of tumor proliferation and cancer response to treatment. The drug was tested on patients with brain tumors. A PET image is a result of the metabolic processes for delivery, uptake, and retention in DNA by the tumor and degradative metabolism in the whole patient. 2-[11C]Thymidine is metabolized to [C11]CO2, which rapidly crosses the blood-brain barrier and distributes throughout the brain. 2-[11C]Thymidine itself is poorly transported by the blood-brain barrier, however, it may intercalate into DNA.